| Company Name: |
Energy Chemical |
| Tel: |
400-0056266 |
| Email: |
marketing1@energy-chemical.com |
|
| Product Name: | RTC13 | | Synonyms: | RTC13;4(5H)-Thiazolone, 2-amino-5-[[5-(2-nitrophenyl)-2-furanyl]methylene]-, (5Z)-;RTC13 >=98% (HPLC);Read-through compound 13;RMA-4134 | | CAS: | 1359825-94-7 | | MF: | C14H9N3O4S | | MW: | 315.3 | | EINECS: | | | Product Categories: | | | Mol File: | 1359825-94-7.mol |  |
| | RTC13 Chemical Properties |
| storage temp. | 2-8°C | | solubility | DMSO: 20mg/mL, clear | | form | Solid | | color | Orange to red | | InChI | 1S/C14H9N3O4S/c15-14-16-13(18)12(22-14)7-8-5-6-11(21-8)9-3-1-2-4-10(9)17(19)20/h1-7H,(H2,15,16,18)/b12-7+ | | InChIKey | CZZAPCPWFCGOCC-KPKJPENVSA-N | | SMILES | O=C1NC(S/C1=C\C2=CC=C(C3=C([N+]([O-])=O)C=CC=C3)O2)=N |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | RTC13 Usage And Synthesis |
| Description | RTC13 is a premature termination codon (PTC) readthrough inducer that acts by restoring dystrophin expression and improving muscle function in the mdx mouse model for Duchenne muscular dystrophy. | | Uses | RTC13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy (DMD)[1]. | | in vivo | | Animal Model: | Wild-type (C57BL/10) mice at 10 to 12 weeks of age[1].
| | Dosage: | 10 (n = 5), 30 (n = 5), 60 (n = 5) or 300 mg/kg (n = 5). | | Administration: | Intraperitoneal Administration. | | Result: | No changes were observed in liver and kidney weights at the time of necropsies, and Hematoxylin and Eosin (H&E) staining revealed the absence of histopathological changes. |
| | References | [1] Refik Kayali, et al. Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. Hum Mol Genet. 2012 Sep 15;21(18):4007-20. DOI:10.1093/hmg/dds223 |
| | RTC13 Preparation Products And Raw materials |
|